Subscribe To
Agios presents updated pyrukynd® (mitapivat) data highlighting long-term safety profile and durable improvement in hemoglobin and markers of hemolysis and ineffective erythropoiesis in non-transfusion
– Actively Enrolling Phase 3 ENERGIZE and ENERGIZE-T Studies Evaluating PYRUKYND® in Adults with Non-transfusion-dependent and Transfusion-dependen...
December 10, 2022, 11:30 pm
Agios presents updated pyrukynd® (mitapivat) data highlighting long-term safety profile and durable improvement in hemoglobin and markers of hemolysis and ineffective erythropoiesis in non-transfusion
– Actively Enrolling Phase 3 ENERGIZE and ENERGIZE-T Studies Evaluating PYRUKYND® in Adults with Non-transfusion-dependent and Transfusion-dependen...
December 10, 2022, 11:30 pm
Agios presents updated pyrukynd® (mitapivat) data highlighting long-term safety profile and durable improvement in hemoglobin and markers of hemolysis and ineffective erythropoiesis in non-transfusion
– Actively Enrolling Phase 3 ENERGIZE and ENERGIZE-T Studies Evaluating PYRUKYND® in Adults with Non-transfusion-dependent and Transfusion-dependen...
December 10, 2022, 11:30 pm
Agios presents updated pyrukynd® (mitapivat) data highlighting long-term safety profile and durable improvement in hemoglobin and markers of hemolysis and ineffective erythropoiesis in non-transfusion
– Actively Enrolling Phase 3 ENERGIZE and ENERGIZE-T Studies Evaluating PYRUKYND® in Adults with Non-transfusion-dependent and Transfusion-dependen...
December 10, 2022, 11:30 pm
Agios presents updated pyrukynd® (mitapivat) data highlighting long-term safety profile and durable improvement in hemoglobin and markers of hemolysis and ineffective erythropoiesis in non-transfusion
– Actively Enrolling Phase 3 ENERGIZE and ENERGIZE-T Studies Evaluating PYRUKYND® in Adults with Non-transfusion-dependent and Transfusion-dependen...
December 10, 2022, 11:30 pm
Agios presents updated pyrukynd® (mitapivat) data highlighting long-term safety profile and durable improvement in hemoglobin and markers of hemolysis and ineffective erythropoiesis in non-transfusion
– Actively Enrolling Phase 3 ENERGIZE and ENERGIZE-T Studies Evaluating PYRUKYND® in Adults with Non-transfusion-dependent and Transfusion-dependen...
December 10, 2022, 11:30 pm
Agios presents updated pyrukynd® (mitapivat) data highlighting long-term safety profile and durable improvement in hemoglobin and markers of hemolysis and ineffective erythropoiesis in non-transfusion
– Actively Enrolling Phase 3 ENERGIZE and ENERGIZE-T Studies Evaluating PYRUKYND® in Adults with Non-transfusion-dependent and Transfusion-dependen...
December 10, 2022, 11:30 pm
Agios presents updated pyrukynd® (mitapivat) data highlighting long-term safety profile and durable improvement in hemoglobin and markers of hemolysis and ineffective erythropoiesis in non-transfusion
– Actively Enrolling Phase 3 ENERGIZE and ENERGIZE-T Studies Evaluating PYRUKYND® in Adults with Non-transfusion-dependent and Transfusion-dependen...
December 10, 2022, 11:30 pm
Agios presents updated pyrukynd® (mitapivat) data highlighting long-term safety profile and durable improvement in hemoglobin and markers of hemolysis and ineffective erythropoiesis in non-transfusion
– Actively Enrolling Phase 3 ENERGIZE and ENERGIZE-T Studies Evaluating PYRUKYND® in Adults with Non-transfusion-dependent and Transfusion-dependen...
December 10, 2022, 11:30 pm
Agios presents updated pyrukynd® (mitapivat) data highlighting long-term safety profile and durable improvement in hemoglobin and markers of hemolysis and ineffective erythropoiesis in non-transfusion
– Actively Enrolling Phase 3 ENERGIZE and ENERGIZE-T Studies Evaluating PYRUKYND® in Adults with Non-transfusion-dependent and Transfusion-dependen...
December 10, 2022, 11:30 pm
Agios presents updated pyrukynd® (mitapivat) data highlighting long-term safety profile and durable improvement in hemoglobin and markers of hemolysis and ineffective erythropoiesis in non-transfusion
– Actively Enrolling Phase 3 ENERGIZE and ENERGIZE-T Studies Evaluating PYRUKYND® in Adults with Non-transfusion-dependent and Transfusion-dependen...
December 10, 2022, 11:30 pm
Tesla begins selling cars in thailand, a growing electric vehicle hotspot
Southeast Asia boasts a population of over 600 million, providing a significantly untapped market for c...
December 9, 2022, 1:59 pm
Village super market: an underrated defensive option
Recent inter-market movement suggests that consumer staple stocks could benefit. Village Super Market h...
December 9, 2022, 1:54 pm
3 no-brainer stocks to buy amid the tech sell-off
Investing in these tech staples can pay off in the long run....
December 9, 2022, 11:30 am
Amazon's tiktok-style feed a smart move but poses challenges, say e-commerce experts
Amazon.com Inc.'s launch of a TikTok-style feed of customized videos and photos is an innovative way to tap...
December 9, 2022, 11:28 am
Are consumer staples stocks lagging mondelez international (mdlz) this year?
Here is how Mondelez (MDLZ) and PepsiCo (PEP) have performed compared to their sector so far this year....
December 9, 2022, 11:17 am
Broadridge taps intrafi to expand reach of securities-based lending
Broadridge Financial Solutions, a US-headquartered fintech company, has announced its partnership with IntraFi, a privately held ...
December 8, 2022, 5:36 pm
Netapp: value stock or value trap?
Investors seeking to derisk their portfolio, yet keep a foot in a cloud-related technology stock, will find Nt...
December 8, 2022, 3:55 pm
Call traders target rkt as stock rallies from lows
Rocket Companies Inc (NYSE:RKT) is seeing a bullish options surge today, with 22,000 calls across the tap...
December 8, 2022, 1:59 pm
5 stocks worth a look in the promising retail-miscellaneous industry
Better pricing, effective inventory management, and merchandise and operational initiatives should buoy Retail - Miscellaneous players. Ulta Beauty (U...
December 8, 2022, 12:03 pm